Preliminary Study of Differentially Expressed Serum Peptides of Advanced NSCLC Patients Responsive to EGFR-TKI and Their Clinical Signiifcance
10.3779/j.issn.1009-3419.2016.09.08
- VernacularTitle:晚期NSCLC患者EGFR-TKI治疗过程中血清多肽变化及其临床意义的探索性研究
- Author:
WANG ZIHE
1
;
TANG CHUANHAO
;
LIU YI
;
XU BIN
;
QIN HAIFENG
;
LEI YANGYANG
;
GAO HONGJUN
;
HE KUN
;
LIU XIAOQING
Author Information
1. 军事医学科学院附属医院肺部肿瘤科
- Keywords:
Matrix-assisted laser desorption/ionization time-of-lfight mass spectrometry;
Cancer proteomics;
Epi-dermal growth factor receptor;
Tyrosine kinase inhibitor;
Lung neoplasms
- From:
Chinese Journal of Lung Cancer
2016;19(9):600-606
- CountryChina
- Language:Chinese
-
Abstract:
Background and objectivehTis study aimed at using matrix-assisted laser desorption ionization - time of lfight mass spectrometer (matrix-assisted laser desorption ionization time-of-lfight mass spectrometry, MALDI-TOF-MS) screening the difference serum peptides during epidermal growth factor tyrosine kinase inhibitors (EGFR-TKIs) treatment and exploring their signiifcance of advanced NSCLC patients.MethodsCollect 102 serum samples from 34 advanced NSCLC pa-tients, which are before TKI treatment, best effect of treatment and atfer progession. Peptides were extracted from the samples and then detected by MALDI-TOF-MS system to get the mass spectra. hTe mass spectra data was analyzed by the Clinpro-ToolTM sotfware to identify the different serum peptides, and then analyzed the clinical signiifcance of peptides.Results Among the 34 patients who received TKI treatment, there were none evaluated as complete response (CR), 11 patients evalu-ated as PR and 23 patients evaluated as stable disease (SD), with the PFS was 8.0 months (95%CI: 6.6-11.2); overall survival (OS) was 11.4 months (95%CI: 10.6-16.5). Atfer detected the serum from three different points of time, the result showed that they were totally different; 87 different peptide peaks were identiifed atfer analysis self-paired serum between the time of best effect and baseline, which included one statistically different [P<0.001, area under curve (AUC)≥0.9] peptide; 96 different peptide peaks were identiifed atfer analysis serum between the time of progression and baseline, which included 3 statistically different (P<0.001, AUC≥0.9) peptides; 115 different peptide peaks were identiifed atfer analysis serum between the time of progression and best effect, which included 4 statistically different (P<0.001, AUC≥0.9) peptides.ConclusionhTeserum peptides of NSCLC patients in the process of TKI treatment are dynamic and the different peptides may be associated with treatment effect and disease progression. However, the features and clinical signiifcance of different peptides need to be vali-dated in the future.
